Treatment Patterns and Survival in Patients with Intermediate, Advanced, or Terminal Stage of Hepatocellular Carcinoma in France over the Period 2015-2017: A Real-Life Study
Table 1
Characteristics of patients with newly identified IAT stage† HCC over the period 2015–2017 in the SNDS database.
Newly diagnosed IAT stage† HCC population
Total
19,649 (100%)
Gender male (%)
16,210 (82.5%)
Age (years) at the identification of IAT stage† HCC: mean (SD)
70.5 (11.0)
Duration of follow-up (month): mean (SD)
7.9 (7.3)
History of HCC curative treatment or type of disease progression
Previous curative treatment
3,205 (16.3%)
No curative treatment (de novo IAT stage† at HCC diagnosis)
13,512 (68.8%)
Undetermined (lack of retrospective data in some patients with HCC diagnosed before 2013)
2,932 (14.9%)
HCC aetiology (several responses possible‡)
Alcohol intake
10,328 (52.6%)
Viral hepatitis
3,635 (18.5%)
Metabolic risk factors§
8,729 (44.4%)
Other liver diseases
11,218 (57.1%)
None identified liver disease in the database
2,596 (13.2%)
†IAT stage: intermediate, advanced, or terminal stage; ‡a single patient can have several HCC risk factors explaining the sum of percentages greater than 100; §Metabolic risk factors are NAFLD (nonalcoholic fatty liver disease), NASH (nonalcoholic steatohepatitis), or diabetes mellitus.